In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK and XenoPort join forces on restless leg/pain agent; terminated

Executive Summary

XenoPort (prodrug candidates for neurological and GI diseases) has licensed GlaxoSmithKline exclusive worldwide rights (excluding Japan, Korea, the Philippines, Indonesia, Thailand, and Taiwan, where Astellas Pharma already has rights) to develop, manufacture, and market XP13512, a gabapentin prodrug in Phase III for restless legs syndrome and Phase II for neuropathic pain.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies